APOL1-Maze
Brief description of study
MZE829-201 is a Phase 2, open-label study of MZE829 in adults aged 18 to 65 years with proteinuric chronic kidney disease (CKD) and the APOL1 high risk genotype, or APOL1 Kidney Disease (AKD). It aims to evaluate the safety and tolerability of MZE829 in adults with proteinuric AKD, to evaluate the change in albuminuria after treatment with MZE829, and to characterize the plasma pharmacokinetics of MZE829.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or